RNA can also be transfected into cells to transiently express its coded protein, or to study
RNA decay kinetics. RNA transfection is often used in primary cells that do not divide.
siRNAs can also be transfected to achieve RNA silencing (i.e. loss of RNA and protein from the targeted gene). This has become a major application in research to achieve "
knock-down" of proteins of interests (e.g. Endothelin-1) with potential applications in gene therapy. Limitation of the silencing approach are the toxicity of the transfection for cells and potential "off-target" effects on the expression of other genes/proteins. RNA can be purified from cells after
lysis or synthesized from free
nucleotides either chemically, or enzymatically using an
RNA polymerase to
transcribe a
DNA template. As with DNA, RNA can be delivered to cells by a variety of means including
microinjection,
electroporation, and
lipid-mediated transfection. If the RNA encodes a
protein, transfected cells may
translate the RNA into the encoded protein. If the RNA is a regulatory RNA (such as a
miRNA), the RNA may cause other changes in the cell (such as
RNAi-mediated knockdown). Encapsulating the RNA molecule in
lipid nanoparticles was a breakthrough for producing viable
RNA vaccines, solving a number of key technical barriers in delivering the RNA molecule into the human cell. RNA molecules shorter than about 25nt (nucleotides) largely evade detection by the
innate immune system, which is triggered by longer RNA molecules. Most cells of the body express proteins of the innate immune system, and upon exposure to exogenous long RNA molecules, these proteins initiate signaling cascades that result in
inflammation. This inflammation hypersensitizes the exposed cell and nearby cells to subsequent exposure. As a result, while a cell can be repeatedly transfected with short RNA with few non-specific effects, repeatedly transfecting cells with even a small amount of long RNA can cause cell death unless measures are taken to suppress or evade the innate immune system (see "Long-RNA transfection" below). Short-RNA transfection is routinely used in biological research to knock down the expression of a protein of interest (using
siRNA) or to express or block the activity of a
miRNA (using short RNA that acts independently of the cell's
RNAi machinery, and therefore is not referred to as siRNA). While DNA-based vectors (
viruses,
plasmids) that encode a short RNA molecule can also be used, short-RNA transfection does not risk modification of the cell's DNA, a characteristic that has led to the development of short RNA as a new class of
macromolecular drugs. Long-RNA transfection is the process of deliberately introducing RNA molecules longer than about 25nt into living cells. A distinction is made between short- and long-RNA transfection because exogenous long RNA molecules elicit an
innate immune response in cells that can cause a variety of nonspecific effects including
translation block,
cell-cycle arrest, and
apoptosis.
Endogenous vs. exogenous long RNA The innate immune system has evolved to protect against
infection by detecting
pathogen-associated molecular patterns (PAMPs), and triggering a complex set of responses collectively known as
inflammation. Many cells express specific
pattern recognition receptors (PRRs) for exogenous RNA including
toll-like receptor 3,7,8 (
TLR3,
TLR7,
TLR8), the RNA
helicase RIG1 (RARRES3),
protein kinase R (PKR, a.k.a. EIF2AK2), members of the oligoadenylate synthetase family of proteins (
OAS1,
OAS2,
OAS3), and others. All of these proteins can specifically bind to exogenous RNA molecules and trigger an immune response. The specific chemical, structural or other characteristics of long RNA molecules that are required for recognition by PRRs remain largely unknown despite intense study. At any given time, a typical
mammalian cell may contain several hundred thousand mRNA and other,
regulatory long RNA molecules. How cells distinguish exogenous long RNA from the large amount of endogenous long RNA is an important open question in
cell biology. Several reports suggest that
phosphorylation of the 5'-end of a long RNA molecule can influence its
immunogenicity, and specifically that 5'-triphosphate RNA, which can be produced during viral infection, is more immunogenic than 5'-diphosphate RNA, 5'-monophosphate RNA or RNA containing no 5' phosphate. However, in vitro-transcribed (ivT) long RNA containing a
7-methylguanosine cap (present in
eukaryotic mRNA) is also highly immunogenic despite having no 5' phosphate, suggesting that characteristics other than 5'-phosphorylation can influence the immunogenicity of an RNA molecule. Eukaryotic mRNA contains chemically modified nucleotides such as
N6-methyladenosine,
5-methylcytidine, and
2'-O-methylated nucleotides. Although only a very small number of these modified nucleotides are present in a typical mRNA molecule, they may help prevent mRNA from activating the innate immune system by disrupting
secondary structure that would resemble double-stranded RNA (dsRNA), == See also ==